New data suggests that 525 mg dose and 700 mg dose responders’ rates are approximately 90% for those HIV patients who pass first 10 weeks of monotherapy without virologic failure CytoDyn has engaged top CCR5 […]
DENVER, March 29, 2019 – Medicine Man Technologies, Inc. (otcqx:MDCL) (“Medicine Man Technologies” or “Company”), a rapidly growing, vertically integrated cannabis operator, today announced that the Company will present at the Spring Investor Summit being held […]
Tarrytown, NY, March 21, 2019 — Nightfood, Inc. (otcqb:NGTF), the innovative company solving America’s $50 billion-dollar nighttime snacking problem, continues to capture the attention of the market with two major national media outlets featuring Nightfood […]
FDA Previously Granted Rolling Review for BLA VANCOUVER, Washington, Mar 18, 2019 – CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential […]
DENVER, March 21, 2019 -Medicine Man Technologies, Inc. (otcqx:MDCL) (“Medicine Man Technologies” or “Company”), a rapidly growing, vertically integrated cannabis operator, today announced it will be presenting at the Sidoti & Company, LLC, Spring 2019 […]
VANCOUVER, Washington, March 11, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that leronlimab (PRO 140), […]
Tarrytown, NY, March 11, 2019 — Nightfood, Inc. (otcqb:NGTF), the innovative company solving America’s $50 billion-dollar nighttime snacking problem, has announced that the second production run of Nightfood ice cream will begin this week, and […]
VANCOUVER, Washington, March 04, 2019 — CytoDyn Inc. (otc.qb:CYDY), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the FDA has reviewed […]
VANCOUVER, Washington, Feb. 27, 2019 — CytoDyn Inc. (OTC.QB: CYDY), a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that data from its study of leronlimab […]
Longmont is northern Colorado’s newest cannabis retailer; Store unveiling comes a month after announcement of binding agreement for near-term acquisition by Medicine Man Technologies, Inc. (OTC: MDCL) DENVER, Feb. 21, 2019 — Medicine Man, Colorado’s leading […]
Tarrytown, NY, Feb 28, 2019 – Nightfood, Inc. (OTC QB: NGTF), the innovative company solving America’s $50 billion-dollar nighttime snacking problem, has announced that over 33,000 consumers across the country have already requested coupons for […]
TARRYTOWN, NY, Feb. 26, 2019 – Nightfood, Inc. (otcqb:NGTF), the innovative company solving America’s $50 billion-dollar nighttime snacking problem, has announced entry into the northern California market through a distribution […]
Based on strong results in its pre-clinical animal study, CytoDyn files for Orphan Drug Designation for Triple-Negative Breast Cancer VANCOUVER, Washington, Feb 20, 2019 – CytoDyn Inc. (otc.qb:CYDY), a biotechnology company developing a novel humanized […]
VANCOUVER, Washington, Feb. 08, 2019 — CytoDyn Inc. (otc.qb:CYDY), CytoDyn, a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that it will be presenting a company overview at BIO […]
VANCOUVER, Washington, Feb 01, 2019 — Successful interim results in the 700 mg monotherapy arm prompted the FDA to allow CytoDyn to switch all remaining combination therapy patients from CD02-Extension study from 350 mg to […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
